Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American ...

Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...

A membrane-free solid-state reactor turns captured carbon dioxideinto clean formic acid that feeds microbes, growing ...

Detailed price information for Artara Therapeutics Inc (TARA-Q) from The Globe and Mail including charting and trades.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal ...

Incyte today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 Data suggest ...

Vadimezan（DMXAA，AbMole，M1999）是一种多生物学活性的小分子化合物，其作用机理主要涉及三个方面：首先，Vadimezan（DMXAA）是一种STING激动剂，可通过激活STING信号通路诱导I型干扰素分泌促进免疫应答；其次，V ...

New research provides evidence that the Alzheimer’s disease drug Lecanemab functions by activating a specific cleaning ...

Kymera Therapeutics, Inc. ( KYMR) Citi Annual Global Healthcare Conference 2025 December 3, 2025 11:15 AM EST ...

A new nanoparticle vaccine successfully prevented several aggressive cancers in mice, including pancreatic and melanoma. The ...